AG003OWJ

73963-72-1 | 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

AG003OWJ

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	73963-72-1
Catalog Number	AG003OWJ(AGN-PC-0U47NZ)
Chemical Name	6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
IUPAC Name	6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
InChI	InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI Key	RRGUKTPIGVIEKM-UHFFFAOYSA-N
MDL Number	MFCD00866780
Molecular Formula	C20H27N5O2
Molecular Weight	369.4607
NSC Number	758936
SMILES	C(CCCOc1cc2c(cc1)NC(=O)CC2)c1n(nnn1)C1CCCCC1
UNII	N7Z035406B
Synonyms	6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, cilostazol, OPC 13013, OPC-13013, Pletal, cilostazol, 73963-72-1, Pletal, Cilostazole, Pletaal, OPC-13013, Cilostazolum, Cilostazolum [INN-Latin], OPC 13013, OPC 21, OPC-21, UNII-N7Z035406B, CHEBI:31401, C20H27N5O2, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, BRN 3632107, 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one, 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one, MLS000028470, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril, MFCD00866780, N7Z035406B, NCGC00015207-07, SMR000058428, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one, DSSTox_CID_25132, DSSTox_RID_80693, DSSTox_GSID_45132, Q-200854, Cilostazol [INN:JAN], 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-, 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-, 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one, CPD000058428, CAS-73963-72-1, Pletal (TN), SR-01000003107, Cilostazol,(S), CILASTAZOL, RETAL, Cilostazol [USAN:USP:INN:BAN:JAN], Tocris-1692, Opera_ID_488, Spectrum2_001118, Spectrum3_001170, Spectrum4_000772, Spectrum5_001762, Lopac-C-0737, CHEMBL799, C 0737, AC1L1EE2, Lopac0_000218, REGID_for_CID_2754, SCHEMBL16128, BSPBio_002759, KBioGR_001184, MLS000758281, MLS000759507, MLS001076067, MLS002153891, SPECTRUM1505230, SPBio_001256, GTPL7148, Cilostazol (JP17/USAN/INN), DTXSID9045132, CTK8F0315, HSDB 8312, KBio3_002259, RRGUKTPIGVIEKM-UHFFFAOYSA-N, ZX-AFC000447, BCPP000279, HMS1922N15, HMS2093M14, HMS2096F16, HMS2234C06, HMS3260L17, HMS3268O09, HMS3654J13, HMS3676B18, HMS3713F16, Pharmakon1600-01505230, ACT02663, BCP03724, ZINC1552174, ZX-AT018851, Tox21_110098, Tox21_500218, 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril, BDBM50225508, BI7396, BS0279, CCG-39646, KM1582, NSC758936, s1294, AKOS015855512, Cilostazol, >=98% (HPLC), powder, OPC 13013; OPC 21; Pletaal, Tox21_110098_1, AC-4334, AM90304, API0002016, BCP9000530, CS-1759, DB01166, KS-5154, LP00218, MCULE-8893820969, NSC-758936, OR13681, RP18108, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, NCGC00015207-01, NCGC00015207-02, NCGC00015207-03, NCGC00015207-04, NCGC00015207-05, NCGC00015207-06, NCGC00015207-08, NCGC00015207-09, NCGC00015207-10, NCGC00015207-11, NCGC00015207-12, NCGC00022153-02, NCGC00022153-04, NCGC00022153-05, NCGC00022153-06, NCGC00022153-07, NCGC00260903-01, AJ-26894, AK111532, AN-12078, CC-25783, CJ-24365, HY-17464, SAM001246734, SAM001247085, SC-14107, BCP0726000145, SBI-0050206.P002, AB0012441, AB2000035, LS-142693, TC-063580, TL8005113, EU-0100218, FT-0602474, FT-0645036, ST24046323, SW199053-2, D01896, J90029, AB00382988-14, AB00382988_15, AB00382988_16, 963C721, A837982, C-21103, SR-01000003107-2, SR-01000003107-4, SR-01000003107-7, BRD-K67017579-001-04-2, BRD-K67017579-001-05-9, BRD-K67017579-001-07-5, BRD-K67017579-001-13-3, BRD-K67017579-001-17-4, SR-01000003107-10, Cilastatin sodium, Antibiotic for Culture Media Use Only, Cilostazol, United States Pharmacopeia (USP) Reference Standard, 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one, 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril, Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material, 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-, 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline, Pletal, Cilostazol, Pleta (TN), Otsuka brand of cilostazol, D03VPC, D0E7MJ, Cilostazol (JP15/USAN/INN), CID2754, RW2759, C20-H27-N5-O2, Cilostazol, 99% - 100MG 100mg, CL23867, CS-O-00531, A4337, C2587, A10217, C045645, D000077407, 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril, 2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-,

Complexity	485
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	369.216g/mol
Formal Charge	0
Heavy Atom Count	27
Hydrogen Bond Acceptor Count	5
Hydrogen Bond Donor Count	1
Isotope Atom Count	0
Molecular Weight	369.469g/mol
Monoisotopic Mass	369.216g/mol
Rotatable Bond Count	7
Topological Polar Surface Area	81.9A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	3.1

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H315-H319-H335
Packing Group
Precautionary statements	P261-P280a-P304+P340-P305+P351+P338-P405-P501a
UN Code

Certificate of Analysis

Lot Number